Ophthotech Corp. (OPHT: Quote) announced after the bell Monday that it has entered into an ex-US licensing and commercialization agreement with Novartis Pharmaceuticals focused on the treatment of wet age-related macular degeneration. Ophthotech has granted Novartis exclusive rights to commercialize Fovista in markets outside the United States.
Ophthotech gapped open sharply higher Tuesday morning, but traded in a range for the majority of the session. The stock finished up by 7.70 at $39.16, with volume at nearly an 8-month high. Ophthotech surged to a 2 1/2 month high.
by RTT Staff Writer
For comments and feedback: email@example.com